Coronary Artery Lesions

The purpose of this study is to check the safety of 3-month dual antiplatelet therapy (DAPT) in patients at high risk of bleeding (HBR) with the approved XIENCE family of coronary drug-eluting stents.

I'M INTERESTED

This research study is led by Dr. Gregory Giugliano.

Contact: Annette Scarnici, RN, CCRC, 413-794-9076

Participation details:

June 01, 2017
BH18-044
Heart
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
  • At least 18 years of age
  • History of major bleeding
  • History of stroke
12 months
Recruiting